Shockwave Medical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Shockwave Medical kazanç ve gelirinin sırasıyla yıllık 13.5% ve 19.4% oranında artması tahmin edilirken, EPS'nin yıllık 10.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

13.5%

Kazanç büyüme oranı

10.9%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	0%
Gelir büyüme oranı	19.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	21 Nov 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BMV:SWAV * - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	1,128	233	N/A	N/A	9
12/31/2024	919	174	221	N/A	11
12/31/2023	727	137	280	N/A	11
9/30/2023	671	244	143	177	N/A
6/30/2023	617	244	126	161	N/A
3/31/2023	557	241	121	150	N/A
12/31/2022	490	216	93	118	N/A
9/30/2022	430	88	69	86	N/A
6/30/2022	364	55	48	61	N/A
3/31/2022	299	29	23	34	N/A
12/31/2021	237	-9	3	15	N/A
9/30/2021	176	-38	-29	-18	N/A
6/30/2021	130	-53	-53	-44	N/A
3/31/2021	84	-71	-75	-64	N/A
12/31/2020	68	-66	-83	-71	N/A
9/30/2020	59	-65	-83	-71	N/A
6/30/2020	51	-65	-77	-66	N/A
3/31/2020	51	-57	-66	-58	N/A
12/31/2019	43	-51	-52	-48	N/A
9/30/2019	34	-48	-48	-45	N/A
6/30/2019	26	-45	-47	-45	N/A
3/31/2019	18	-44	-47	-45	N/A
12/31/2018	12	-41	-43	-41	N/A
12/31/2017	2	-31	-31	-30	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SWAV * 'nin tahmini kazanç büyümesi (yıllık 13.5% ) tasarruf oranının ( 7.7% ) üzerindedir.

Kazançlar ve Piyasa: SWAV * şirketinin kazançlarının (yıllık 13.5% ) MX pazarından (yıllık 11.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: SWAV * şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: SWAV * şirketinin gelirinin (yıllık 19.4% ) MX pazarından (yıllık 7.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SWAV * şirketinin gelirinin (yıllık 19.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SWAV * 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Shockwave Medical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Chief Accounting Officer recently sold Mex$22m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022

ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022

Independent Director recently sold Mex$7.9m worth of stock

Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Key Executive recently sold Mex$17m worth of stock

Key Executive recently sold Mex$17m worth of stock

ShockWave Medical, Inc. Announces Executive Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ShockWave Medical, Inc. Provides Revenue Guidance for the Full Year 2022

ShockWave Medical, Inc. Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin